

Daily evidence digest

4 May 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Human genetic epidemiology of COVID-19, pathophysiology of COVID-19 ARDS and MIS-C in children, mRNA vaccine effectiveness over time

Peer reviewed journals featured:

- A narrative review on the human genetic epidemiology of COVID-19 [here](#)
- Observational studies on:
 - Pathophysiological pathway differences in children with COVID-19 ARDS and COVID-19 induced MIS-C [here](#)
 - Comparative effectiveness over time of mRNA vaccines [here](#)
 - Impact of COVID-19 on female breast, colorectal and non-small cell lung cancer incidence, stage, and healthcare pathway to diagnosis in Wales [here](#)
- A machine learning-based model for prediction of clinical deterioration in hospitalised patients [here](#)

Letters and correspondence discussed:

- Real-world studies on the effectiveness of COVID-19 vaccines [here](#)
- Concerns over Molnupiravir trials [here](#), [here](#) and [here](#)

Pre-peer review articles featured:

- Epidemiological and clinical features of SARS-CoV-2 infection in children during the Omicron outbreak in Shanghai [here](#)
- A systematic review on the effectiveness of COVID-19 vaccines against the Omicron variant [here](#)
- Evidence for aerosol transfer of SARS-CoV2-specific humoral immunity [here](#)

Guidance and reports

- The Therapeutic Goods Administration (TGA) released updates on the provisional approval for Pfizer Australia - COMIRNATY (tozinameran) booster in 12-15 year olds [here](#)

[Click here](#) to subscribe to the daily evidence digest.